Soligenix News - SNGX

Company Name	Stock Ticker Symbol	Market	Type
Soligenix Inc	SNGX	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.042	10.97%	0.425	19:25:43

Open Price	Low Price	High Price	Close Price	Prev Close
0.3764	0.3764	0.44	0.427	0.383

more quote information »

Recent News

Date	Time	Source	Heading
4/25/2024	8:52	IHNW	FeaturedCannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA
4/25/2024	07:30	PRNUS	Soligenix Extends Patent Protection for its Filovirus..
4/18/2024	08:30	PRNUS	Soligenix Announces Pricing of $4.75 Million Public Offering
4/15/2024	07:30	PRNUS	FDA Grants Soligenix Orphan Drug Designation for the..
4/11/2024	07:30	PRNUS	FDA Grants Soligenix Orphan Drug Designation for the..
4/03/2024	07:30	PRNUS	Soligenix Announces Agreement on the Design of a Second..
3/15/2024	07:30	PRNUS	Soligenix Announces Recent Accomplishments and Year End 2023..
2/08/2024	07:30	PRNUS	Soligenix Announces Formation of Behçet's Disease Medical..
1/25/2024	07:30	PRNUS	Soligenix to Present at The Microcap Conference
1/08/2024	07:30	PRNUS	FDA Grants Soligenix "Fast Track" Designation for Dusquetide..
1/04/2024	07:30	PRNUS	Soligenix Announces Top-line Results of the Phase 2a Study..
1/02/2024	07:30	PRNUS	Soligenix Announces Publication Demonstrating Complete..
12/22/2023	16:05	EDGAR2	Form 8-K - Current report
12/18/2023	00:15	EDGAR2	Form EFFECT - Notice of Effectiveness
12/15/2023	16:10	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/15/2023	16:10	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/15/2023	16:10	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/15/2023	16:10	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/15/2023	16:03	EDGAR2	Form 8-K - Current report
12/08/2023	17:12	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/08/2023	17:11	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/08/2023	17:10	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/08/2023	17:10	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/08/2023	16:05	EDGAR2	Form S-3/A - Registration statement under Securities Act of..
12/01/2023	07:30	PRNUS	"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma"..
11/30/2023	07:30	PRNUS	Soligenix Receives FDA IND Clearance for Phase 2 Clinical..
11/17/2023	16:05	EDGAR2	Form 8-K - Current report
11/17/2023	16:00	PRNUS	Soligenix, Inc. Announces Adjournment of Annual Meeting,..
11/13/2023	16:00	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/13/2023	07:30	PRNUS	Soligenix Announces Recent Accomplishments And Third Quarter..
10/20/2023	16:05	EDGAR2	Form 8-K - Current report
10/20/2023	16:00	PRNUS	Soligenix, Inc. Announces Adjournment of Annual Meeting,..
10/17/2023	13:00	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
10/17/2023	13:00	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
10/16/2023	16:45	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
10/16/2023	07:30	PRNUS	Soligenix to Present at The ThinkEquity Conference
10/13/2023	13:00	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
9/25/2023	07:30	PRNUS	Soligenix Announces Achievement of Two-Year Stability with..
9/22/2023	16:06	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
9/22/2023	16:05	EDGAR2	Form 8-K - Current report
9/22/2023	16:00	PRNUS	Soligenix, Inc. Announces Adjournment of Annual Meeting,..
9/15/2023	16:10	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
9/15/2023	16:05	EDGAR2	Form 8-K - Current report
8/30/2023	16:05	EDGAR2	Form S-3 - Registration statement under Securities Act of..
8/21/2023	17:17	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/21/2023	07:30	PRNUS	Soligenix Announces Recent Accomplishments And Second..
8/14/2023	16:09	EDGAR2	Form NT 10-Q - Notification of inability to timely file Form..
8/10/2023	07:30	PRNUS	HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell..
8/07/2023	16:07	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
8/07/2023	16:05	EDGAR2	Form DEF 14A - Other definitive proxy statements
7/11/2023	07:30	PRNUS	Soligenix Announces Expansion of SGX302 (Synthetic..